Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: The total number of infections climbed to 41,495. “In the past 24 hours we had 117 new deaths and 3,186 new confirmed cases of people infected with the coronavirus,” Kianush Jahanpur told state TV, calling on Iranians to stay at home. Iran has had an intercity travel ban since Thursday and the government has extended the closure of universities and schools and the suspension of all cultural, religious and sports events. “If necessary, we might impose tougher measures as our priority is the nation’s safety and health,” said Iran’s first Vice President, Eshaq Jahangiri, according to state TV. Iran last week warned of a surge of cases as many Iranians ignored calls to avoid traveling for Persian New Year holidays that started on March 20. To stem the spread of the virus in crowded jails, Iran’s judiciary on Sunday extended furloughs for 100,000 prisoners. On March 17, Iran said it had freed about 85,000 people from jail temporarily, including political prisoners. Iranian media on Monday, citing the governor of Iran’s Fars province, Enayatollah Rahimi, reported that prisoners at one prison “broke cameras and caused other damage in two sections of the prison where violent criminals are kept”. The state news agency IRNA said similar riots had erupted in other prisons since March 20. Families have called for the release of all prisoners. Claim: Iran plans tougher restrictions as coronavirus toll rises.

A: Iran had 117 new coronavirus deaths in the last 24 hours, bringing the total to 2,757, a health ministry spokesman said on Monday, prompting the Middle East’s worst hit country to consider tougher curbs on movement.
****
Q: Paragraph: Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company’s most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved. The trial tested the pill in post-menopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body. “We are delighted with the final data,” Pfizer said in a release, adding the company will discuss the successful data on progression-free survival with the U.S. Food and Drug Administration “to determine next steps” for palbociclib. A secondary goal of the study is to determine whether palbociclib can prolong overall survival. But Pfizer spokeswoman Sally Beatty said the company does not yet have such data, because it takes longer periods to follow patients and gauge survival trends. Although Pfizer is conducting two larger late-stage trials of palbociclib, ISI Group analyst Mark Schoenebaum noted the company has previously said it might discuss with the FDA the potential to seek approval of the medicine based upon mid-stage trial data, if the data warranted. Palbociclib, which blocks enzymes known as cyclin-dependent kinases (CDKs) 4 and 6, was taken in combination with a standard treatment called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of advanced breast cancer cases. Letrozole is the chemical name of Femara, a Novartis AG drug that belongs to a class of treatments called aromatase inhibitors that block production of estrogen. Pfizer on Monday did not present detailed data from the trial results, saying they would be presented at a scientific meeting in San Diego in April. The success of the trial, called Paloma-1, follows highly favorable interim data that Pfizer unveiled in December 2012. At that point in the study, those taking both palbociclib and letrozole went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not palbociclib. The 18.6-month difference was considered statistically significant. Side effects from palbociclib were similar to those previously reported, Pfizer said on Monday. The earlier interim results had shown that patients taking the drug combination experienced anemia, fatigue and neutropenia - a decline in white blood cells called neutrophils that can put patients at higher risk of infection. Palbociclib was designated a “breakthrough” drug by the FDA last April based on initial data from the trial. The FDA grants “breakthrough” status to drugs that may offer substantial improvement over existing treatments for serious or life-threatening diseases. The status helps to speed up the approval process. Pfizer has started two late-stage trials of the drug - Paloma-2 and Paloma-3 - in patients with advanced breast cancer. Paloma-2 will test the same drug combination, palbociclib and letrozole, as an initial treatment for breast cancer. Paloma-3 will evaluate palbociclib in combination with another hormone therapy, fulvestrant, in women whose cancer has progressed after hormonal therapy. The drug, sold under the brand name Faslodex by AstraZeneca Plc, is called an estrogen receptor antagonist. Companies trying to develop treatments similar to palbociclib include Novartis and Eli Lilly & Co. Breast cancer killed more than 508,000 women worldwide in 2011, according to the World Health Organization. Pfizer shares were up 3.7 percent at $31.53 on Monday morning on the New York Stock Exchange. Claim: Pfizer breast cancer drug succeeds in mid-stage trial.

A: Pfizer Inc’s experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study’s primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.
****
Q: Paragraph: In a report released Wednesday, the experts said annual cases of Legionnaires’ jumped more than fivefold from 2000 to 2017, and that as many as 70,000 Americans get the disease every year. Legionnaires’ is caused by bacteria that can thrive in buildings with large water systems. About 20 outbreaks are reported each year, including recent ones at an Atlanta hotel and a hospital near Chicago. But there is no single set of widely accepted guidelines for preventing infections. The National Academies of Sciences, Engineering and Medicine report pushes for requirements like minimum temperature levels for hot-water heaters, and registration and monitoring of cooling towers. Claim: Experts call for steps to stem increases in Legionnaires’.

A:
Top U.S. science experts are calling for stronger policies to combat the growing Legionnaires’ disease problem.
****